Founded in August 2013 and based in South China Modern Chinese Medicine Park, Nanlang, Zhongshan City, Guangdong Province, Zhongshan Wanhan Pharmaceutical Co., Ltd. (referred to as "The Company" hereinafter), with a registered capital of more than 18 million, is a certified National High-Tech Enterprise focusing on activities throughout R&D, manufacturing and distribution of pharmaceutical products and related services.

The Company is a subsidiary of Besunyen Holdings, a company listed on the main board of Hong Kong, and is headquartered in the South China Modern Chinese Medicine Park, Zhongshan city, Guangdong Province. It covers an area of more than 100 acres and has invested nearly 300 million. Since the establishment of The Company, it has been guided by scientific research, decent management and pragmatic management as its philosophy. It has developed rapidly in business, and the production capacity and business scale has been keeping expanding. It has been rated as "The National High-tech Enterprise" and "Guangzhou Medical University Teaching Base" for the new R & D institutions in Guangdong Province

At present, having already built 30, 000 square meters of production workshops for pharmaceutical preparations that comply with the new version of GMP and 10, 000 square meters of production and auxiliary workshops for APIs. The Company has R & D, production and sales capabilities of semi-synthetic and synthetic APIs, solid oral preparations, medicinal Pellicles, eye drops, medical devices, disinfection products, etc. The OTC product for the weight loss, Orlistat, has become the industry's leader of single-product, and sales volume ranked the first place in the domestic market in 2019. Production lines of the Classmedical device and disinfection product have also been certified as per new version of the GMP and entered the production and sales stage. In addition, The Company has also built the sterile workshop for eye drops and passed the certification of workshop for GMP topical medicines.

The Company is primarily focused on the R&D, manufacturing and distribution of pellicles, eye drops, APIs, intermediates for APIs, etc.

The main products are orlistat; Povidone iodine pellicle for gynecological diseases, which is a high-tech product and the only pellicle product for povidone iodine nationwide; Various types of eye drops for ophthalmic diseases. Among them, the annual production capacity of capsule preparations can reach 2 billion units.

The production of APIs and intermediates for APIs are mainly directed for orlistat (API and intermediates) and oseltamivir (API).

The Company has formed a complete system and structure of five business entities: Process development, QC, QA, registration declaration, information & intellectual property rights. It has established laboratories for fermentation, synthesis, pilot-scale synthesis, formulation development, and analysis and test center. The Company has successfully completed a series of product development and registration applications, results of some of which are published in core journals such as Org. Biomol. Chem.

The Company's R&D team consists of high-tech products and several post-doctoral and well-educated personnel experienced in the field of pharmaceutical R&D, which represents the leading level of the pharmaceutical industry and provides Wanhan with sustainable resources for innovation. Now the Company holds a number of valid patents in various categories, of which 20 are of invention, 4 of utility model and 1 of design, and has filed a total of 40 patent applications for invention.